ORBITA-2 is a double blinded randomised placebo-controlled trial comparing the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy. Follow-up will be at 12 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
439
Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
Basildon and Thurrock Hospitals NHS Foundation Trust
Basildon, United Kingdom
Royal Bournemouth Hospital
Bournemouth, United Kingdom
Wycombe Hospital
High Wycombe, United Kingdom
Imperial College Healthcare NHS Trust
London, United Kingdom
Change in angina symptom score between groups
Time frame: 12 weeks
Change in treadmill exercise time
Time frame: 12 weeks
Angina severity as assessed by Canadian Cardiovascular Society class
Time frame: 12 weeks
Physical limitation, angina stability, quality of life, angina frequency, freedom from angina as assessed with the Seattle Angina Questionnaire
Time frame: 12 weeks
Quality of life as assessed with the EQ-5D-5L questionnaire
Time frame: 12 weeks
Change in dobutamine stress echocardiography score
Time frame: 12 weeks
Need for anti-anginal medication introduction and up-titration
Time frame: 12 weeks
Admission for acute coronary syndrome or unscheduled coronary angiography
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Royal Free Hospital
London, United Kingdom
Queen Alexandra Hospital
Portsmouth, United Kingdom
Royal Berkshire NHS Foundation Trust
Reading, United Kingdom
Harefield Hospital
Uxbridge, United Kingdom